DK3689865T3 - Hidtil ukendte aminopyrimidinderivater - Google Patents

Hidtil ukendte aminopyrimidinderivater Download PDF

Info

Publication number
DK3689865T3
DK3689865T3 DK20158961.1T DK20158961T DK3689865T3 DK 3689865 T3 DK3689865 T3 DK 3689865T3 DK 20158961 T DK20158961 T DK 20158961T DK 3689865 T3 DK3689865 T3 DK 3689865T3
Authority
DK
Denmark
Prior art keywords
ukendte
hidtil
aminopyrimidinderivater
ukendte aminopyrimidinderivater
hidtil ukendte
Prior art date
Application number
DK20158961.1T
Other languages
English (en)
Inventor
Daniela Angst
Francois Gessier
Anna Vulpetti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3689865T3 publication Critical patent/DK3689865T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
DK20158961.1T 2013-11-29 2014-11-28 Hidtil ukendte aminopyrimidinderivater DK3689865T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13195081 2013-11-29
EP17191467.4A EP3299368B1 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives

Publications (1)

Publication Number Publication Date
DK3689865T3 true DK3689865T3 (en) 2023-06-19

Family

ID=49674216

Family Applications (3)

Application Number Title Priority Date Filing Date
DK20158961.1T DK3689865T3 (en) 2013-11-29 2014-11-28 Hidtil ukendte aminopyrimidinderivater
DK17191467.4T DK3299368T3 (da) 2013-11-29 2014-11-28 Hidtil ukendte aminopyrimidinderivater
DK14821285.5T DK3074386T3 (da) 2013-11-29 2014-11-28 Nye aminopyrimidinderivater

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK17191467.4T DK3299368T3 (da) 2013-11-29 2014-11-28 Hidtil ukendte aminopyrimidinderivater
DK14821285.5T DK3074386T3 (da) 2013-11-29 2014-11-28 Nye aminopyrimidinderivater

Country Status (43)

Country Link
US (6) US9512084B2 (da)
EP (4) EP4219478A1 (da)
JP (2) JP6342495B2 (da)
KR (2) KR102421388B1 (da)
CN (2) CN105683181B (da)
AP (1) AP2016009158A0 (da)
AR (1) AR098549A1 (da)
AU (1) AU2014356069B2 (da)
BR (1) BR112016010397B1 (da)
CA (1) CA2926908C (da)
CL (1) CL2016001055A1 (da)
CR (1) CR20160244A (da)
CU (1) CU24384B1 (da)
CY (3) CY1119705T1 (da)
DK (3) DK3689865T3 (da)
EA (1) EA031218B1 (da)
EC (1) ECSP16054826A (da)
ES (3) ES2947770T3 (da)
FI (1) FI3689865T3 (da)
HK (2) HK1223368A1 (da)
HR (3) HRP20230585T1 (da)
HU (3) HUE037588T2 (da)
IL (1) IL244943B (da)
JO (1) JO3314B1 (da)
LT (3) LT3299368T (da)
MA (1) MA39055B1 (da)
MX (1) MX367911B (da)
MY (2) MY191381A (da)
NO (1) NO3074386T3 (da)
NZ (1) NZ718835A (da)
PE (1) PE20160869A1 (da)
PH (1) PH12016500791A1 (da)
PL (3) PL3299368T3 (da)
PT (3) PT3689865T (da)
RS (3) RS64275B1 (da)
SI (3) SI3689865T1 (da)
SV (1) SV2016005206A (da)
TN (1) TN2016000128A1 (da)
TW (1) TWI652261B (da)
UA (1) UA117256C2 (da)
UY (1) UY35858A (da)
WO (1) WO2015079417A1 (da)
ZA (1) ZA201602275B (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
IL293603B2 (en) 2014-04-07 2024-03-01 Novartis Ag Cancer treatment using chimeric antigen receptor (CAR) against CD19
CN112481283A (zh) 2014-07-21 2021-03-12 诺华股份有限公司 使用cd33嵌合抗原受体治疗癌症
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
CN106687483B (zh) 2014-07-21 2020-12-04 诺华股份有限公司 使用人源化抗-bcma嵌合抗原受体治疗癌症
US20170209492A1 (en) 2014-07-31 2017-07-27 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
MY189028A (en) 2014-08-19 2022-01-20 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
DK3194443T3 (da) 2014-09-17 2021-09-27 Novartis Ag Målretning af cytotoksiske celler med kimære receptorer i forbindelse med adoptiv immunterapi
SG11201702895SA (en) 2014-10-08 2017-05-30 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CU20170052A7 (es) 2014-10-14 2017-11-07 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
EP3280795B1 (en) * 2015-04-07 2021-03-24 Novartis AG Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
SI3280729T1 (sl) 2015-04-08 2022-09-30 Novartis Ag Terapije CD20, terapije CD22 in kombinacija terapij s celico, ki izraža himerni antigenski receptor CD19 (CAR)
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
SI3317301T1 (sl) 2015-07-29 2021-10-29 Novartis Ag Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
CA3007671A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
JP7082055B2 (ja) 2015-12-22 2022-06-07 ノバルティス アーゲー 抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体（ｃａｒ）およびｐｄ－ｌ１阻害剤に対する抗体
EP3423482A1 (en) 2016-03-04 2019-01-09 Novartis AG Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
KR102565885B1 (ko) 2016-07-20 2023-08-09 유니버시티 오브 유타 리서치 파운데이션 Cd229 car t 세포 및 이의 사용 방법
AR110676A1 (es) 2016-10-07 2019-04-24 Novartis Ag Tratamiento del cáncer utilizando receptores de antígenos quiméricos
US20200078400A1 (en) 2016-12-03 2020-03-12 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2018223101A1 (en) 2017-06-02 2018-12-06 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
JP2020526194A (ja) 2017-06-29 2020-08-31 ジュノー セラピューティクス インコーポレイテッド 免疫療法薬と関連する毒性を評価するためのマウスモデル
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
KR20200116077A (ko) 2017-11-01 2020-10-08 주노 쎄러퓨티크스 인코퍼레이티드 B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드
CA3080904A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
AR113796A1 (es) * 2017-11-06 2020-06-10 Lilly Co Eli Compuestos inhibidores de tirosina cinasa de bruton (btk)
CN111989106A (zh) 2017-12-01 2020-11-24 朱诺治疗学股份有限公司 基因工程化细胞的给药和调节方法
CN108069911A (zh) * 2017-12-14 2018-05-25 中国药科大学 6－氨基－2－苯基嘧啶类化合物、制备方法和医药用途
EP3724225A1 (en) 2017-12-15 2020-10-21 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
WO2019241426A1 (en) 2018-06-13 2019-12-19 Novartis Ag Bcma chimeric antigen receptors and uses thereof
CN112424207B (zh) 2018-07-25 2024-03-19 诺华股份有限公司 Nlrp3炎性小体抑制剂
WO2020092848A2 (en) 2018-11-01 2020-05-07 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
WO2020092854A2 (en) 2018-11-01 2020-05-07 Juno Therapeutics, Inc. Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
JP2022513062A (ja) 2018-11-16 2022-02-07 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞悪性腫瘍を処置するために、操作されたｔ細胞を投薬する方法
JP2022513685A (ja) 2018-11-30 2022-02-09 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法を用いた処置のための方法
PE20212198A1 (es) 2019-01-29 2021-11-16 Juno Therapeutics Inc Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1)
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
JP2022534216A (ja) * 2019-05-23 2022-07-28 ノバルティス アーゲー Ｂｔｋ阻害剤の結晶形態
CA3138081A1 (en) 2019-05-23 2020-11-26 Novartis Ag Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor
BR112021023110A2 (pt) * 2019-05-23 2022-04-12 Novartis Ag Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
WO2020234780A1 (en) 2019-05-23 2020-11-26 Novartis Ag Methods of treating asthma using a bruton's tyrosine kinase inhibitor
EP4081514A1 (en) * 2019-12-23 2022-11-02 Biogen MA Inc. Btk inhibitors
KR20230009386A (ko) 2020-04-10 2023-01-17 주노 쎄러퓨티크스 인코퍼레이티드 Ｂ-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
CN116209444A (zh) * 2020-08-14 2023-06-02 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物的晶型及其制备方法
WO2022034529A1 (en) 2020-08-14 2022-02-17 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
KR20230134560A (ko) 2021-01-26 2023-09-21 노파르티스 아게 약학적 조성물
EP4313023A1 (en) 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
IL310975A (en) 2021-09-03 2024-04-01 Novartis Ag LOU064 for the treatment of multiple sclerosis
JP2024504267A (ja) 2021-12-14 2024-01-31 ノバルティス アーゲー Ｌｏｕ０６４を使用した治療の方法
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors
WO2024031091A2 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
WO2024069507A1 (en) 2022-09-30 2024-04-04 Novartis Ag Synthesis methods and intermediates for the production of remibrutinib
CN117024354B (zh) * 2023-10-08 2023-12-08 天津凯莱英制药有限公司 瑞米布替尼的制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
AU2002236692A1 (en) 2000-10-23 2002-05-21 Bristol-Myers Squibb Company Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase, their identification and use
KR20080014934A (ko) 2000-11-07 2008-02-14 노파르티스 아게 단백질 키나제 ｃ 억제제로서의 인돌릴말레이미드 유도체
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
AR039209A1 (es) 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida
EP2322202A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune diseases
AU2003297740B2 (en) 2002-12-09 2008-09-11 The Board Of Regents Of The University Of Texas System Methods for selectively inhibiting Janus tyrosine kinase 3 (Jak3)
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
CA2524048C (en) 2003-05-19 2013-06-25 Irm Llc Immunosuppressant compounds and compositions
CA2545427C (en) 2004-01-12 2012-08-21 Cytopia Research Pty Ltd Selective kinase inhibitors
BRPI0608252A2 (pt) 2005-03-10 2010-04-06 Cgi Pharmaceuticals Inc entidades quìmicas, composições farmacêuticas compreendendo as mesmas, métodos utilizando as referidas entidades quìmicas e uso das referidas entidades quìmicas
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
US20100160292A1 (en) 2006-09-11 2010-06-24 Cgi Pharmaceuticals, Inc Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
EP2081435B1 (en) 2006-09-22 2016-05-04 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
SI2134374T1 (sl) 2007-03-14 2014-03-31 Bionsil S.R.L. In Liquidazione Inhibitorji btk za rabo pri zdravljenju na kemoterapevtska zdravila rezistentnih epitelijskih tumorjev
ES2554615T3 (es) 2008-05-06 2015-12-22 Gilead Connecticut, Inc. Amidas sustituidas, método de preparación y utilización como inhibidores de Btk
PE20110164A1 (es) 2008-07-02 2011-03-28 Hoffmann La Roche Nuevas fenilpirazinonas como inhibidores de quinasa
EP3311818A3 (en) 2008-07-16 2018-07-18 Pharmacyclics, LLC Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
US20100261776A1 (en) 2008-11-07 2010-10-14 The Research Foundation Of State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
ES2513915T3 (es) 2009-04-24 2014-10-27 F. Hoffmann-La Roche Ag Inhibidores de la tirosina quinasa de Bruton
US8853193B2 (en) * 2010-02-26 2014-10-07 Boehringer Ingelheim International Gmbh Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
CN103889962B (zh) 2011-04-01 2017-05-03 犹他大学研究基金会 作为受体酪氨酸激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物
DK2710007T3 (da) 2011-05-17 2020-01-27 Principia Biopharma Inc Kinasehæmmere
HUE059230T2 (hu) 2011-06-10 2022-10-28 Merck Patent Gmbh Vegyületek és eljárások BTK-inhibitor aktivitású pirimidin és piridin vegyületek elõállítására
BR112013033534A2 (pt) 2011-06-28 2017-02-07 Pharmacyclics Inc métodos e composições para inibição de reabsorção de osso
CN103732596B (zh) 2011-07-08 2016-06-01 诺华股份有限公司 吡咯并嘧啶衍生物
EP3778896A1 (en) 2011-08-09 2021-02-17 Fred Hutchinson Cancer Research Center Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
KR20230109775A (ko) 2011-10-19 2023-07-20 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(btk)의 억제제의 용도
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
RU2014126750A (ru) 2011-12-09 2016-01-27 Ф. Хоффманн-Ля Рош Аг Ингибиторы тирозинкиназы брутона
CN104169260A (zh) 2012-03-09 2014-11-26 卡尔那生物科学株式会社 新三嗪衍生物
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
JP6182593B2 (ja) 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
US9133134B2 (en) 2012-05-16 2015-09-15 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
BR112015002590A2 (pt) 2012-08-10 2019-08-06 Boehringer Ingelheim Int compostos heteroaromáticos como inibidores de tirosina cinase de bruton (btk)
EP3680238A1 (en) 2012-10-04 2020-07-15 University of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives

Also Published As

Publication number Publication date
EP3074386B1 (en) 2017-10-11
MA39055A1 (fr) 2018-02-28
MX2016006908A (es) 2016-08-17
CU24384B1 (es) 2019-03-04
EA031218B1 (ru) 2018-12-28
HUE037588T2 (hu) 2018-09-28
UY35858A (es) 2015-06-30
EP3074386A1 (en) 2016-10-05
JP6667573B2 (ja) 2020-03-18
RS60251B1 (sr) 2020-06-30
US20180251432A1 (en) 2018-09-06
BR112016010397B1 (pt) 2023-04-11
KR102421388B1 (ko) 2022-07-18
CN110172056B (zh) 2022-04-19
SI3074386T1 (en) 2018-02-28
US11673868B2 (en) 2023-06-13
CY1122924T1 (el) 2021-10-29
CA2926908A1 (en) 2015-06-04
CN110172056A (zh) 2019-08-27
AP2016009158A0 (en) 2016-04-30
PL3074386T3 (pl) 2018-03-30
US20220041561A1 (en) 2022-02-10
EP3689865A1 (en) 2020-08-05
JO3314B1 (ar) 2019-03-13
US11180460B2 (en) 2021-11-23
ES2655527T3 (es) 2018-02-20
HK1223368A1 (zh) 2017-07-28
HUE049794T2 (hu) 2020-10-28
RS56657B1 (sr) 2018-03-30
TN2016000128A1 (en) 2017-10-06
CY1126056T1 (el) 2023-11-15
CN105683181B (zh) 2019-04-23
SI3299368T1 (sl) 2020-07-31
EP3299368B1 (en) 2020-02-26
CL2016001055A1 (es) 2016-10-28
LT3074386T (lt) 2017-12-27
KR20160088877A (ko) 2016-07-26
US20160235746A1 (en) 2016-08-18
EP4219478A1 (en) 2023-08-02
PL3689865T3 (pl) 2023-07-31
MY179059A (en) 2020-10-26
NZ718835A (en) 2021-12-24
SV2016005206A (es) 2016-11-21
ECSP16054826A (es) 2017-10-31
JP2018141005A (ja) 2018-09-13
HRP20200775T1 (hr) 2020-07-24
PE20160869A1 (es) 2016-09-08
KR20220044370A (ko) 2022-04-07
PT3689865T (pt) 2023-06-16
AR098549A1 (es) 2016-06-01
TWI652261B (zh) 2019-03-01
CR20160244A (es) 2016-07-29
HRP20171999T1 (hr) 2018-02-09
BR112016010397A8 (pt) 2020-04-22
CU20160078A7 (es) 2016-09-30
HUE062248T2 (hu) 2023-10-28
LT3689865T (lt) 2023-07-10
DK3074386T3 (da) 2018-01-22
PH12016500791B1 (en) 2016-06-13
CN105683181A (zh) 2016-06-15
PT3299368T (pt) 2020-05-28
UA117256C2 (uk) 2018-07-10
WO2015079417A1 (en) 2015-06-04
US9512084B2 (en) 2016-12-06
US20150152068A1 (en) 2015-06-04
DK3299368T3 (da) 2020-05-25
PL3299368T3 (pl) 2020-08-10
MX367911B (es) 2019-09-11
CA2926908C (en) 2021-10-26
AU2014356069B2 (en) 2017-06-15
SI3689865T1 (sl) 2023-07-31
IL244943B (en) 2020-04-30
MY191381A (en) 2022-06-22
KR102380539B1 (ko) 2022-03-29
JP6342495B2 (ja) 2018-06-13
MA39055B1 (fr) 2018-10-31
RS64275B1 (sr) 2023-07-31
EA201691125A1 (ru) 2016-09-30
FI3689865T3 (fi) 2023-06-12
NO3074386T3 (da) 2018-03-10
IL244943A0 (en) 2016-05-31
HRP20230585T1 (hr) 2023-09-01
LT3299368T (lt) 2020-05-25
ES2791525T3 (es) 2020-11-04
ES2947770T3 (es) 2023-08-18
US20230312483A1 (en) 2023-10-05
ZA201602275B (en) 2017-08-30
PT3074386T (pt) 2017-11-15
TW201609666A (zh) 2016-03-16
CY1119705T1 (el) 2018-06-27
US20200010426A1 (en) 2020-01-09
JP2016538313A (ja) 2016-12-08
AU2014356069A1 (en) 2016-05-05
EP3689865B1 (en) 2023-03-29
EP3299368A1 (en) 2018-03-28
US10457647B2 (en) 2019-10-29
PH12016500791A1 (en) 2016-06-13
HK1252317A1 (zh) 2019-05-24

Similar Documents

Publication Publication Date Title
DK3689865T3 (en) Hidtil ukendte aminopyrimidinderivater
DK3088517T3 (en) Humant anti-il-33-neutraliserende monoklonalt antistof
DK3736291T3 (en) Anti-FCRH5-antistoffer
DK3354246T3 (en) Udstyrsmonteringssystem
DK3077519T3 (en) Cmv-vacciner
EP3000028A4 (en) AUTOMATIC ADDING TO AN AGENDA
EP2957205A4 (en) HAND DRYER
DK3470074T3 (en) Probiotika
EP2970310A4 (en) 5-Bromo-indirubins
EP2853297A4 (en) kendama
DK3056208T3 (en) Immunpotentiator
DK2979701T3 (en) Antitumormiddel indbefattende irinotecanhydrochloridhydrat
AU353644S (en) Stamphousing
EP3014557A4 (en) TELEPHONE ON FILE
GB201300001D0 (en) Envirep - environment replicater
DK2989854T3 (en) Strømstyret opvarmningssystem
AU4899P (en) Herbie53 Iresine herbstii
AU4953P (en) Flogazora Gazania rigens
AU4977P (en) Harrosy Gaura lindheimeri
AU353327S (en) Kettlebell
AU353331S (en) Kettlebell
AU353329S (en) Kettlebell
AU353328S (en) Kettlebell
AU353326S (en) Kettlebell
AU353325S (en) Kettlebell